An Electronic Questionnaire for Liver Assessment in Congenital Disorders of Glycosylation (LeQCDG)

A Patient-Centered Study

D Marques-da-Silva, R Francisco, V Dos Reis Ferreira, L Forbat, R Lagoa, P A Videira, P Witters, J Jaeken, D Cassiman

Research output: Contribution to journalArticle

Abstract

Congenital disorders of glycosylation (CDG) are ultra-rare diseases showing a great phenotypic diversity ranging from mono- to multi-organ/multisystem involvement. Liver involvement, mostly nonprogressive, is often reported in CDG patients. The main objectives of this work were (1) to better understand liver involvement in CDG patients through a liver electronic questionnaire targeting CDG families (LeQCDG) and (2) to compare responses from LeQCDG participants with literature review regarding the prevalence of liver disease and the occurrence of liver symptoms in CDG patients. The network of patient advocacy groups, families and professionals (CDG & Allies - PPAIN) developed the LeQCDG by adapting validated published questionnaires. The LeQCDG was approved by an ethics committee, and the recruitment of patients and caregivers proceeded through social media platforms. Participants were asked to report past or present liver-related symptoms (e.g. hepatomegaly, liver fibrosis and cirrhosis) and laboratory results (e.g. biochemical and/or radiological). From 11 December 2016 to 22 January 2017, 155 questionnaires were completed. Liver disease was present in 29.9% of CDG patients. Main symptoms reported included hepatomegaly, increased levels of serum transaminases, fibrosis, steatosis and cirrhosis. The data obtained in this online survey confirm findings from a recent literature review of 25 years of published evidence (r = 0.927, P = 0.02). Our questionnaire collected large amounts of meaningful, clinical and patient-oriented data in a short period of time without geographic limitations. Internet-based approaches are especially relevant in the context of ultra-rare diseases such as CDG.

Original languageEnglish
Pages (from-to)1-10
JournalJIMD reports
DOIs
Publication statusE-pub ahead of print - 15 Jul 2018

Fingerprint

Congenital Disorders of Glycosylation
Liver
Hepatomegaly
Rare Diseases
Liver Cirrhosis
Liver Diseases
Fibrosis
Social Media
Patient Advocacy
Ethics Committees
Surveys and Questionnaires
Transaminases
Internet
Patient Selection
Caregivers

Keywords

  • Congenital disorder(s) of glycosylation (CDG)
  • Literature review
  • Liver
  • PMM2-CDG
  • Questionnaire
  • Rare diseases

Cite this

Marques-da-Silva, D ; Francisco, R ; Dos Reis Ferreira, V ; Forbat, L ; Lagoa, R ; Videira, P A ; Witters, P ; Jaeken, J ; Cassiman, D. / An Electronic Questionnaire for Liver Assessment in Congenital Disorders of Glycosylation (LeQCDG) : A Patient-Centered Study. In: JIMD reports. 2018 ; pp. 1-10.
@article{ae9e581f82704a17acca6dff976ecab7,
title = "An Electronic Questionnaire for Liver Assessment in Congenital Disorders of Glycosylation (LeQCDG): A Patient-Centered Study",
abstract = "Congenital disorders of glycosylation (CDG) are ultra-rare diseases showing a great phenotypic diversity ranging from mono- to multi-organ/multisystem involvement. Liver involvement, mostly nonprogressive, is often reported in CDG patients. The main objectives of this work were (1) to better understand liver involvement in CDG patients through a liver electronic questionnaire targeting CDG families (LeQCDG) and (2) to compare responses from LeQCDG participants with literature review regarding the prevalence of liver disease and the occurrence of liver symptoms in CDG patients. The network of patient advocacy groups, families and professionals (CDG & Allies - PPAIN) developed the LeQCDG by adapting validated published questionnaires. The LeQCDG was approved by an ethics committee, and the recruitment of patients and caregivers proceeded through social media platforms. Participants were asked to report past or present liver-related symptoms (e.g. hepatomegaly, liver fibrosis and cirrhosis) and laboratory results (e.g. biochemical and/or radiological). From 11 December 2016 to 22 January 2017, 155 questionnaires were completed. Liver disease was present in 29.9{\%} of CDG patients. Main symptoms reported included hepatomegaly, increased levels of serum transaminases, fibrosis, steatosis and cirrhosis. The data obtained in this online survey confirm findings from a recent literature review of 25 years of published evidence (r = 0.927, P = 0.02). Our questionnaire collected large amounts of meaningful, clinical and patient-oriented data in a short period of time without geographic limitations. Internet-based approaches are especially relevant in the context of ultra-rare diseases such as CDG.",
keywords = "Congenital disorder(s) of glycosylation (CDG), Literature review, Liver, PMM2-CDG, Questionnaire, Rare diseases",
author = "D Marques-da-Silva and R Francisco and {Dos Reis Ferreira}, V and L Forbat and R Lagoa and Videira, {P A} and P Witters and J Jaeken and D Cassiman",
note = "Sem pdf. Funda{\cc}{\~a}o para a Ci{\^e}ncia e Tecnologia for the grant SFRH/BD/124326/2016",
year = "2018",
month = "7",
day = "15",
doi = "10.1007/8904_2018_121",
language = "English",
pages = "1--10",
journal = "JIMD reports",
issn = "2192-8304",
publisher = "Springer Berlin",

}

Marques-da-Silva, D, Francisco, R, Dos Reis Ferreira, V, Forbat, L, Lagoa, R, Videira, PA, Witters, P, Jaeken, J & Cassiman, D 2018, 'An Electronic Questionnaire for Liver Assessment in Congenital Disorders of Glycosylation (LeQCDG): A Patient-Centered Study', JIMD reports, pp. 1-10. https://doi.org/10.1007/8904_2018_121

An Electronic Questionnaire for Liver Assessment in Congenital Disorders of Glycosylation (LeQCDG) : A Patient-Centered Study. / Marques-da-Silva, D; Francisco, R; Dos Reis Ferreira, V; Forbat, L; Lagoa, R; Videira, P A; Witters, P; Jaeken, J; Cassiman, D.

In: JIMD reports, 15.07.2018, p. 1-10.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An Electronic Questionnaire for Liver Assessment in Congenital Disorders of Glycosylation (LeQCDG)

T2 - A Patient-Centered Study

AU - Marques-da-Silva, D

AU - Francisco, R

AU - Dos Reis Ferreira, V

AU - Forbat, L

AU - Lagoa, R

AU - Videira, P A

AU - Witters, P

AU - Jaeken, J

AU - Cassiman, D

N1 - Sem pdf. Fundação para a Ciência e Tecnologia for the grant SFRH/BD/124326/2016

PY - 2018/7/15

Y1 - 2018/7/15

N2 - Congenital disorders of glycosylation (CDG) are ultra-rare diseases showing a great phenotypic diversity ranging from mono- to multi-organ/multisystem involvement. Liver involvement, mostly nonprogressive, is often reported in CDG patients. The main objectives of this work were (1) to better understand liver involvement in CDG patients through a liver electronic questionnaire targeting CDG families (LeQCDG) and (2) to compare responses from LeQCDG participants with literature review regarding the prevalence of liver disease and the occurrence of liver symptoms in CDG patients. The network of patient advocacy groups, families and professionals (CDG & Allies - PPAIN) developed the LeQCDG by adapting validated published questionnaires. The LeQCDG was approved by an ethics committee, and the recruitment of patients and caregivers proceeded through social media platforms. Participants were asked to report past or present liver-related symptoms (e.g. hepatomegaly, liver fibrosis and cirrhosis) and laboratory results (e.g. biochemical and/or radiological). From 11 December 2016 to 22 January 2017, 155 questionnaires were completed. Liver disease was present in 29.9% of CDG patients. Main symptoms reported included hepatomegaly, increased levels of serum transaminases, fibrosis, steatosis and cirrhosis. The data obtained in this online survey confirm findings from a recent literature review of 25 years of published evidence (r = 0.927, P = 0.02). Our questionnaire collected large amounts of meaningful, clinical and patient-oriented data in a short period of time without geographic limitations. Internet-based approaches are especially relevant in the context of ultra-rare diseases such as CDG.

AB - Congenital disorders of glycosylation (CDG) are ultra-rare diseases showing a great phenotypic diversity ranging from mono- to multi-organ/multisystem involvement. Liver involvement, mostly nonprogressive, is often reported in CDG patients. The main objectives of this work were (1) to better understand liver involvement in CDG patients through a liver electronic questionnaire targeting CDG families (LeQCDG) and (2) to compare responses from LeQCDG participants with literature review regarding the prevalence of liver disease and the occurrence of liver symptoms in CDG patients. The network of patient advocacy groups, families and professionals (CDG & Allies - PPAIN) developed the LeQCDG by adapting validated published questionnaires. The LeQCDG was approved by an ethics committee, and the recruitment of patients and caregivers proceeded through social media platforms. Participants were asked to report past or present liver-related symptoms (e.g. hepatomegaly, liver fibrosis and cirrhosis) and laboratory results (e.g. biochemical and/or radiological). From 11 December 2016 to 22 January 2017, 155 questionnaires were completed. Liver disease was present in 29.9% of CDG patients. Main symptoms reported included hepatomegaly, increased levels of serum transaminases, fibrosis, steatosis and cirrhosis. The data obtained in this online survey confirm findings from a recent literature review of 25 years of published evidence (r = 0.927, P = 0.02). Our questionnaire collected large amounts of meaningful, clinical and patient-oriented data in a short period of time without geographic limitations. Internet-based approaches are especially relevant in the context of ultra-rare diseases such as CDG.

KW - Congenital disorder(s) of glycosylation (CDG)

KW - Literature review

KW - Liver

KW - PMM2-CDG

KW - Questionnaire

KW - Rare diseases

U2 - 10.1007/8904_2018_121

DO - 10.1007/8904_2018_121

M3 - Article

SP - 1

EP - 10

JO - JIMD reports

JF - JIMD reports

SN - 2192-8304

ER -